Commercial plan pharmacy benefit coverage updates

Quick reference guide

We routinely evaluate prescription benefit coverage to help ensure we offer our members affordable and effective medication options. The following summary highlights prescription drug list (PDL) updates for most UnitedHealthcare commercial plans that have pharmacy benefits, **effective Jan. 1, 2024.**

Medications with new benefit coverage

The following medications were not previously covered for most UnitedHealthcare commercial benefit plans.

| Therapeutic use | Medication | Tier |
|----------------------------|--|--------|
| ADHD | amphetamine/dextroamphetamine extended-release (generic Adderall XR®) | Tier 2 |
| ADHD | methylphenidate hydrochloride extended-release (generic Concerta®) | Tier 2 |
| Asthma | QVAR RediHaler® | Tier 1 |
| Asthma/COPD | fluticasone/salmeterol Diskus (Wixela Inhub® [generic Advair Diskus®]) | Tier 3 |
| Cancer | bexarotene capsule (generic Targretin®) | Tier 2 |
| Cancer | bexarotene gel (generic Targretin) | Tier 3 |
| Diabetes | Insulin Lispro Junior KwikPen® (unbranded Humalog® Junior KwikPen) | Tier 2 |
| Diabetes | Insulin Lispro KwikPen (unbranded Humalog KwikPen) | Tier 2 |
| Diabetes | Insulin Lispro Protamine/Insulin Lispro KwikPen Mix75/25 (unbranded Humalog Mix75/25™ KwikPen) | Tier 2 |
| Diabetes | Insulin Lispro vial (unbranded Humalog) | Tier 1 |
| Inflammatory bowel disease | mesalamine delayed-release (generic Delzicol®) | Tier 2 |
| Inflammatory bowel disease | mesalamine delayed-release (generic Lialda®) | Tier 2 |
| Mental health | asenapine maleate sublingual (generic Saphris®) | Tier 3 |
| Neutropenia | Udenyca® | Tier 2 |



Tier updates

The following medications will change tiers.

| Therapeutic use | Medication | Tier | Alternative treatment option(s) |
|----------------------------|--|-------------------------|--------------------------------------|
| Asthma/COPD | Fluticasone propionate/ Salmeterol (Airduo® Respiclick® authorized brand alternative) | Tier 2 to Tier 3 | Arnuity™ Ellipta® and QVAR RediHaler |
| Cancer | Brukinsa ^{®1} | Tier 2 to Tier 3 | Calquence®1 and Imbruvica®1 |
| Inflammatory bowel disease | Apriso® (brand only) | Tier 2 to Tier 1 | N/A |
| Neutropenia | Neulasta® | Tier 3 to Tier 2 | N/A |

Exclusions^{2,3}

We'll no longer cover the following medications. Please see our recommended alternative treatment options.

| Therapeutic use | Medication | Alternative treatment option(s) |
|-----------------|---|--|
| Acne | Finacea® gel (brand only) | azelaic acid gel (generic Finacea) |
| ADHD | Adderall XR (brand only) | amphetamine/dextroamphetamine extended- release 24hr (generic Adderall XR) |
| ADHD | Concerta (brand only) | methylphenidate extended-release osmotic release (generic Concerta) |
| ADHD | Vyvanse® (brand only) | lisdexamfetamine dimesylate (generic Vyvanse) |
| Asthma | Flovent® Diskus® | Arnuity Ellipta and QVAR RediHaler |
| Asthma | Flovent HFA | Arnuity Ellipta and QVAR RediHaler |
| Asthma | Fluticasone propionate HFA (Flovent HFA authorized brand alternative) ⁴ | Arnuity Ellipta and QVAR RediHaler |
| Asthma | Pulmicort Flexhaler™ | Arnuity Ellipta and QVAR RediHaler |
| Asthma/COPD | Advair Diskus (brand only) | fluticasone propionate/salmeterol (generic Advair Diskus) |
| Asthma/COPD | Fluticasone/Salmeterol HFA (Advair HFA authorized brand alternative) ⁴ | fluticasone propionate/salmeterol (generic Advair Diskus), Advair HFA, Breo Ellipta and Symbicort® |
| Asthma/COPD | Fluticasone/Vilanterol Ellipta (Breo Ellipta authorized brand alternative) ⁴ | fluticasone propionate/salmeterol (generic Advair Diskus), Advair HFA, Breo Ellipta and Symbicort |



| Therapeutic use | Medication | Alternative treatment option(s) |
|----------------------------|-------------------------------------|--|
| Cancer | Targretin capsules (brand only) | bexarotene capsule (generic Targretin) |
| Cancer | Targretin gel (brand only) | bexarotene gel (generic Targretin) |
| Diabetes | Humalog Tempo Pen™4 | Humalog KwikPen, Insulin Lispro KwikPen (unbranded Humalog) and Lyumjev™ KwikPen |
| Diabetes | Humalog vial | Insulin Lispro vial (unbranded Humalog) |
| Diabetes | Kombiglyze® XR (brand only) | saxagliptin/metformin extended-release (generic Kombiglyze XR) |
| Diabetes | Lyumjev Tempo Pen⁴ | Humalog KwikPen, Insulin Lispro KwikPen (unbranded Humalog) and Lyumjev KwikPen |
| Diabetes | Onglyza® (brand only) | saxagliptin (generic Onglyza) |
| Diabetes | Rezvoglar™ Kwikpen⁴ | Lantus® and Toujeo® |
| Ear infections | Ciprodex® (brand only) | ciprofloxacin/dexamethasone otic (generic Ciprodex) |
| Heart failure | BiDil® (brand only) | isosorbide dinitrate/hydralazine (generic BiDil) |
| HIV | Prezista® (brand only) | darunavir (generic Prezista) |
| Hypercholesterolemia | Ezetimibe/Atorvastatin ⁴ | simvastatin/ezetimibe (generic Vytorin®) and ezetimibe (generic Zetia®) in combination with atorvastatin (generic Lipitor®) |
| Hypertension | Edarbi [®] | candesartan (generic Atacand®), irbesartan (generic Avapro®), losartan (generic Cozaar®), olmesartan (generic Benicar®), telmisartan (generic Micardis®) and valsartan (generic Diovan®) |
| Hypertension | Edarbyclor [®] | candesartan HCT (generic Atacand HCT®), irbesartan HCT (generic Avalide®), losartan HCT (generic Hyzaar®), olmesartan HCT (Benicar HCT®), valsartan HCT (generic Diovan HCT®) or chlorthalidone (generic Thalitone) in combination with a single-ingredient angiotensin receptor blocker |
| Inflammatory bowel disease | Lialda (brand only) | mesalamine delayed-release (generic Delzicol), mesalamine delayed-release (generic Lialda), Apriso |
| Inflammatory bowel disease | Uceris® rectal foam (brand only) | budesonide rectal foam (generic Uceris) |



| Therapeutic use | Medication | Alternative treatment option(s) |
|------------------------------|---------------------------------------|---|
| Inflammatory conditions | Abrilada ^{®1,4} | Adalimumab-adaz (unbranded Hyrimoz®)¹, Amjevita™¹, Cyltezo®¹, Hadlima™¹ and Humira®¹ |
| Inflammatory conditions | Adalimumab-fkjp ^{1,4} | Adalimumab-adaz (unbranded Hyrimoz) ¹ , Amjevita ¹ , Cyltezo ¹ , Hadlima ¹ and Humira ¹ |
| Inflammatory conditions | Hulio® ^{1,4} | Adalimumab-adaz (unbranded Hyrimoz) ¹ , Amjevita ¹ , Cyltezo ¹ , Hadlima ¹ and Humira ¹ |
| Inflammatory conditions | Hyrimoz ^{1,4} | Adalimumab-adaz (unbranded Hyrimoz) ¹ , Amjevita ¹ , Cyltezo ¹ , Hadlima ¹ and Humira ¹ |
| Inflammatory conditions | Idacio®1,4 | Adalimumab-adaz (unbranded Hyrimoz) ¹ , Amjevita ¹ , Cyltezo ¹ , Hadlima ¹ and Humira ¹ |
| Inflammatory conditions | Yuflyma ^{®1,4} | Adalimumab-adaz (unbranded Hyrimoz) ¹ , Amjevita ¹ , Cyltezo ¹ , Hadlima ¹ and Humira ¹ |
| Inflammatory conditions | Yusimry ^{™1,4} | Adalimumab-adaz (unbranded Hyrimoz) ¹ , Amjevita ¹ , Cyltezo ¹ , Hadlima ¹ and Humira ¹ |
| Mental health | Latuda® (brand only) | lurasidone (generic Latuda) |
| Mental health | Saphris (brand only) | asenapine maleate sublingual tablet (generic Saphris) |
| Multiple sclerosis | Aubagio® (brand only)¹ | teriflunomide (generic Aubagio) ¹ |
| Narcolepsy | Xyrem [®] brand ¹ | armodafinil (generic Nuvigil®), modafinil (generic Provigil®), Sodium Oxybate [Xyrem authorized generic (Hikma)]1, Sunosi®1, Wakix®1 and Xywav ^{TM1} |
| Neutropenia | Ziextenzo™ | Neulasta, Udenyca |
| Oral steroid | Cortisone ⁴ | hydrocortisone (generic Cortef®) |
| Overactive bladder | Oxybutynin 5 mg/5 mL⁴ | oxybutynin oral syrup (generic Ditropan®) |
| Ulcers, heartburn and reflux | Konvomep ^{™4} | lansoprazole orally disintegrating tablet (generic Prevacid® Solu-tab™)¹, Nexium® Suspension¹, OTC - Nexium, Prevacid, Prilosec® and Zegerid® |



Step therapy changes^{5,6}

Step therapy requires members to try a lower-cost medication (step 1) before we approve coverage for a higher-cost medication (step 2). These medications have a new or revised step therapy program.

| Therapeutic use | Medication | Step 1 medications |
|-----------------|---|---|
| Cancer | Mekinist® in combination with Tafinlar® | Where both combinations have similar indications, members new to therapy must try Zelboraf® in combination with Cotellic® |

Supply limit changes

Supply limits establish the maximum quantity of a medication drug that is covered for each copay or in a specified time frame. These medications are now part of the supply limits program.

| Therapeutic use | Medication | Step 1 medications |
|-----------------|-------------------|--------------------|
| Blood disorders | Promacta® 12.5 mg | 62 packets/month |
| Blood disorders | Promacta 25 mg | 186 packets/month |

Benefit coverage is determined by the member's pharmacy benefit plan. This means that there may be medications listed on the PDL that are not covered under a particular member's pharmacy benefit plan. Medications may change in cost or coverage.



¹We may require step therapy or prior authorization for us to cover this medication.

²Exclusion includes brand, generic and authorized generic products, unless otherwise noted.

 $^{^3\!\}text{For}$ benefits that don't exclude these medications, we may require step therapy or prior authorization.

⁴Newly released medication we excluded from coverage at the time of launch and will continue to be excluded from the pharmacy benefit.

⁵Referred to as First Start in New Jersey.

⁶Applies to new utilizers only. Current utilizers on these medications will have continuation of therapy.